Financial Results

Showing 2745 articles
Business

AbCellera Biologics: A Valuation Crossroads After Volatile Returns

Shares of antibody discovery firm AbCellera Biologics (ABCL) present a complex picture for investors, with strong one-year gains overshadowed by steep declines over longer horizons. As the stock trades near $3.86, a significant gap emerges between its market price and some analyst fair value estimates, raising questions about its premium valuation in a challenging biotech market.

Business

Vodafone's Meteoric Rise: Is the Telecom Giant Still a Bargain After a 62% Surge?

Vodafone Group's shares have soared over 62% in the past year, dramatically outperforming the broader market. As the stock consolidates near £1.06, investors are grappling with a critical question: does the rally still have legs, or has the value opportunity evaporated? A deep dive into cash flow and valuation metrics suggests the story may be more complex than the headline numbers imply.

Business

Nvidia Aided China's DeepSeek In Advancing Powerful AI Models Later Linked To Military Use, House Committee Chair Alleges: Report

A U.S. lawmaker has alleged that Nvidia Corp (NASDAQ:NVDA) provided technical assistance to Chinese AI startup DeepSeek. Nvidia Technical Support Allegedly Boosted DeepSeek's Efficiency Nvidia helped DeepSeek improve the efficiency of its artificial intelligence models, according to a letter sent to the U.S. Commerce Department by Rep. John Moolenaar (R-Mich.), chair of the House Select Committee on China. The letter, seen by Reuters on Wednesday, says documents obtained by the committee show th